Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 The long half‐life of 89Zr (t1/2 = 3.3 days) is favorable not only for evaluating the in vivo distribution of monoclonal antibodies, but for various applications other than immuno-PET.
Joon-Kee Yoon
 + 925 word(s) 925 2020-06-18 12:58:43

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Yoon, J.; Park, B.; Ryu, E.; An, Y.; Lee, S. 89Zr-PET Imaging Other than Immuno-PET. Encyclopedia. Available online: https://encyclopedia.pub/entry/1162 (accessed on 30 April 2024).
Yoon J, Park B, Ryu E, An Y, Lee S. 89Zr-PET Imaging Other than Immuno-PET. Encyclopedia. Available at: https://encyclopedia.pub/entry/1162. Accessed April 30, 2024.
Yoon, Joon-Kee, Bok-Nam Park, Eun-Kyoung Ryu, Young-Sil An, Su-Jin Lee. "89Zr-PET Imaging Other than Immuno-PET" Encyclopedia, https://encyclopedia.pub/entry/1162 (accessed April 30, 2024).
Yoon, J., Park, B., Ryu, E., An, Y., & Lee, S. (2020, June 22). 89Zr-PET Imaging Other than Immuno-PET. In Encyclopedia. https://encyclopedia.pub/entry/1162
Yoon, Joon-Kee, et al. "89Zr-PET Imaging Other than Immuno-PET." Encyclopedia. Web. 22 June, 2020.
89Zr-PET Imaging Other than Immuno-PET
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms21124309

89Zr is an emerging radionuclide that plays an essential role in immuno‐positron emission tomography (PET) imaging. Immuno‐PET combines the sensitivity of PET with the specificity of antibodies, and thus is useful for predicting the efficacy of radioimmunotherapy and antibody therapies, imaging target expression, detecting target‐expressing tumors, and the monitoring of anti‐cancer chemotherapies. PET using 89Zr is not confined to antibody imaging. In this review, we discuss 89Zr‐PET applications other than immuno‐PET.

positron emission tomography 89Zr monoclonal antibody oncological imaging

89Zr-Labeled Nanoparticles PET

Various radionuclides including 198Au, 111In, 64Cu, 125mTe, 188Re, 166Ho, and 99mTc have been used for nanoparticle-based nuclear medicine imaging and therapy [1]. Dozens of studies concerning 89Zr-labeled NPs have already been reported, although only a few are clinical. Researchers suggest that 89Zr-labeled NPs (liposomal NPs, nanocolloids, mesoporous silica NPs, dextran NPs, chitosan NPs, etc.) are also promising for tumor detection, the development of nanoparticle drugs, the monitoring of drug delivery, inflammation imaging, and tumor-associated macrophage (TAM) imaging.

TAMs lead to disease progression in cancer cells by modulating the tumor microenvironment and are thus potential targets for anti-cancer therapy. To predict the efficacy of anti-TAM therapy, it is crucial to monitor the quantity and distribution of TAMs. 89Zr-labeled natural high-density lipoprotein (HDL) and dextran NPs showed favorable tumor uptake [2][3]. The co-localization of these radiotracers with a macrophage was revealed by histology and fluorescent imaging [2][3]. These results suggest that 89Zr-labeled NPs can be a good tool for monitoring anti-TAM therapy.

Several studies presented evidence for 89Zr-labeled nanocolloidal albumin as a PET imaging agent for sentinel lymph mapping [4][5][6][7]. In patients with early colon cancers or oral cavity cancers, PET detected sentinel lymph nodes with a very high sensitivity [6][7]. Due to the long half-life of 89Zr, sentinel lymph node mapping using 89Zr-NPs has the advantages of accomplishing both PET imaging and intraoperative probe detection via the single injection of a radiotracer, even though surgical procedures are performed on another day.

89Zr-labeled NPs for atherosclerotic plaques are good examples of inflammation imaging. HDL mimetic infusion has been studied for years as a method to reduce cardiovascular risk. One of the reasons for the failure of HDL mimetic infusion is its low target delivery. 89Zr-labeled natural HDLs and HDL mimetics are delivered to atherosclerotic plaques by being trapped in the macrophages[8][9]. The uptake of 89Zr-labeled HDL mimetics, CER-001, was slightly higher in plaques than in non-plaque walls and correlated well with the contrast enhancement by magnetic resonance imaging (98). Recent animal studies revealed that 89Zr-labeled dextran or hyaluronan NPs have the ability to detect atherosclerotic plaques and monitor anti-inflammatory therapy [10][11].

89Zr-Induced Cerenkov Luminescence Imaging and Therapy

The Cerenkov effect was characterized by Pavel A. Cerenkov in 1934 as the radiation emitted when charged particles (β+, β−, α) travel through an optically transparent insulating material with a velocity that exceeds the speed of light. Cerenkov luminescence imaging has been exploited in a number of preclinical studies. The β+ particles emitted by 89Zr also produce Cerenkov luminescence. Using 89Zr-J591 and luminescence imaging, prostate cancers were visualized in animal models [12].

Photodynamic therapy requires external light to activate the photosensitizers for cancer therapy. Cerenkov radiation from 89Zr can be used as a light source for this purpose. 89Zr-labeled mesoporous silica NPs have 89Zr and photosensitizers inside their hollows. In a breast cancer model, the tumor suppression effect was greater for the 89Zr-labeled mesoporous silica NPs than for the NPs only, or for the control [13]. The advantage of 89Zr over conventional approaches is that 89Zr’s long half-life facilitates long-term photodynamic therapy.

Cell Tracking with 89Zr

Due to its old modality, radiolabeled leukocytes, cell tracking is nothing new for nuclear medicine imaging. Thus, it has already been adopted for various types of cell tracking. Using nuclear medicine imaging to evaluate the early distribution and viability of radiolabeled stem cells is a notable example [14]. With the development of cancer immunotherapy, tracking therapeutic cells is becoming more important for predicting the effectiveness of a therapy. 89Zr has a favorable physical half-life for tracking cells in vivo. Additionally, similar to 111In-oxine, 89Zr-oxine can be labeled to cells directly.

Chimeric antigen receptor (CAR) T-cells are transduced to locate specific targets on the surface of tumors. A few drawbacks of CAR T-cells include their poor tumor-targeting ability and normal tissue toxicity [15]. The prediction of therapeutic efficacy by cell tracking is critical to overcome these shortcomings. Direct labeling with 89Zr-oxine allowed the visualization of CAR T-cell migration to tumors in a glioblastoma model [16]. Labeling with 89Zr-oxine did not affect the viability and function of cells. The fragmented antibody F(ab’)2 for T-cell receptors is another candidate that showed high sensitivity for T-cells in an animal model. Transduced cells as small as 4.7 × 104 were detected via PET imaging, and the tumor uptake quantity was proportional to the number of injected cells [17].

89Zr-desferrioxamine-N-chlorosuccinimide (DBN) is also actively studied as a direct cell labeling method. Unlike 89Zr-oxine, 89Zr-DBN binds covalently to the amine groups of cell surface membrane proteins [18]. Although the labeling efficiency was low to moderate (30~50%), 89Zr-DBN was stably bound to human mesenchymal stem cells (hMSCs) for up to 7 days without deteriorating the cellular viability [18]. PET imaging using 89Zr-hMSC that were delivered to the adventitia of the outflow vein of arteriovenous fistula allowed to track transplanted hMSCs for 3 weeks [19]. More than 90% of the transplanted cells were detected at the site of delivery on day 4, which was decreased by 20% on day 21 [19]. 89Zr-DBN was also labeled to hepatocytes with a labeling efficiency of 20% [20]. The initial amount of homing cells and the subsequent retention was monitored up to 48 h by PET imaging [20].

References

  1. Leila Farzin; Shahab Sheibani; Mohammad Esmaeil Moassesi; Mojtaba Shamsipur; An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions. Journal of Biomedical Materials Research Part A 2018, 107, 251-285, 10.1002/jbm.a.36550.
  2. Carlos Perez-Medina; Jun Tang; Dalya Abdel-Atti; Brandon Hogstad; Miriam Merad; Edward A Fisher; Zahi A. Fayad; Jason S. Lewis; Willem J. M. Mulder; Thomas Reiner; et al. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. Journal of Nuclear Medicine 2015, 56, 1272-1277, 10.2967/jnumed.115.158956.
  3. Edmund J. Keliher; Jeongsoo Yoo; Matthias Nahrendorf; Jason S. Lewis; Brett Marinelli; Andita Newton; Mikael J. Pittet; Ralph Weissleder; Jeonsoo Yoo; 89Zr-Labeled Dextran Nanoparticles Allow in Vivo Macrophage Imaging. Bioconjugate Chemistry 2011, 22, 2383-2389, 10.1021/bc200405d.
  4. Derrek A. Heuveling; Gerard W.M. Visser; Marian Baclayon; Wouter H. Roos; Gijs J.L. Wuite; Otto S. Hoekstra; C. René Leemans; Remco De Bree; G. A. M. S. Van Dongen; 89Zr-Nanocolloidal Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Node Detection in Head and Neck Cancer: Preclinical Results. Journal of Nuclear Medicine 2011, 52, 1580-1584, 10.2967/jnumed.111.089557.
  5. D. A. Heuveling; A. Van Schie; Danielle J. Vugts; N. H. Hendrikse; M. Yaqub; O. S. Hoekstra; K.H. Karagozoglu; C. R. Leemans; G. A. M. S. Van Dongen; Remco De Bree; et al. Pilot Study on the Feasibility of PET/CT Lymphoscintigraphy with 89Zr-Nanocolloidal Albumin for Sentinel Node Identification in Oral Cancer Patients. Journal of Nuclear Medicine 2013, 54, 585-589, 10.2967/jnumed.112.115188.
  6. Derrek A. Heuveling; K. Hakki Karagozoglu; Arthur Van Lingen; Otto S. Hoekstra; Guus A. M. S. Van Dongen; Remco De Bree; Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe.. EJNMMI Research 2018, 8, 15, 10.1186/s13550-018-0368-6.
  7. M. Ankersmit; O. S. Hoekstra; A. Van Lingen; E. Bloemena; M. A. J. M. Jacobs; D. J. Vugts; H. J. Bonjer; G. A. M. S. Van Dongen; W. J. H. J. Meijerink; Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer. European Journal of Nuclear Medicine and Molecular Imaging 2019, 46, 1495-1505, 10.1007/s00259-019-04284-w.
  8. Kang He Zheng; Fleur M. Van Der Valk; Loek P. Smits; Mara Sandberg; Jean-Louis Dasseux; Rudi Baron; Ronald Barbaras; Constance Keyserling; Bram F. Coolen; A.J. Nederveen; et al.Hein J. VerberneThijs E. NellDanielle J. VugtsRaphael DuivenvoordenZahi FayadWillem J. M. MulderGuus Van DongenErik S.G. Stroes HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis 2016, 251, 381-388, 10.1016/j.atherosclerosis.2016.05.038.
  9. Carlos Perez-Medina; Tina Binderup; Mark E. Lobatto; Jun Tang; Claudia Calcagno; Luuk Giesen; Chang Ho Wessel; Julia Witjes; Seigo Ishino; Samantha Baxter; et al.Yiming ZhaoSarayu RamachandranMootaz EldibBrenda L. Sánchez-GaytánPhilip M. RobsonJason BiniJuan F. GranadaKenneth Michael FishErik S. G. StroesRaphael DuivenvoordenSotirios TsimikasJason S. LewisThomas ReinerValentin FusterAndreas KjaerEdward A FisherZahi A. FayadWillem J. M. Mulder In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. JACC: Cardiovascular Imaging 2016, 9, 950-961, 10.1016/j.jcmg.2016.01.020.
  10. Thijs Beldman; Max L. Senders; Amr Alaarg; Carlos Perez-Medina; Jun Tang; Yiming Zhao; Francois Fay; Jacqueline Deichmöller; Benjamin Born; Emilie Desclos; et al.Nicole N. Van Der WelRon A. HoebeFortune KohenElena KartvelishvilyMichal NeemanThomas ReinerClaudia CalcagnoZahi A. FayadMenno P.J. De WintherEsther LutgensWillem J. M. MulderEwelina Kluza Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. ACS Nano 2017, 11, 5785-5799, 10.1021/acsnano.7b01385.
  11. Maulik D. Majmudar; Jeongsoo Yoo; Edmund J. Keliher; Jessica J Truelove; Yoshiko Iwamoto; Brena Sena; Partha Dutta; Anna Borodovsky; Kevin Fitzgerald; Marcelo F Di Carli; et al.Peter LibbyDaniel G. AndersonFilip K. SwirskiRalph WeisslederMatthias Nahrendorf Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circulation Research 2013, 112, 755-761, 10.1161/CIRCRESAHA.111.300576.
  12. A. Ruggiero; Jason P. Holland; Jason S. Lewis; Jan Grimm; Cerenkov luminescence imaging of medical isotopes. Journal of Nuclear Medicine 2010, 51, 1123-1130, 10.2967/jnumed.110.076521.
  13. Anyanee Kamkaew; Feng Chen; Yonghua Zhan; Rebecca L. Majewski; Weibo Cai; Scintillating Nanoparticles as Energy Mediators for Enhanced Photodynamic Therapy. ACS Nano 2016, 10, 3918-3935, 10.1021/acsnano.6b01401.
  14. Mick M. Welling; Marjolijn Duijvestein; Alberto Signore; Louise Van Der Weerd; In vivo biodistribution of stem cells using molecular nuclear medicine imaging. Journal of Cellular Physiology 2011, 226, 1444-1452, 10.1002/jcp.22539.
  15. Zijun Zhao; Yu Chen; Ngiambudulu M. Francisco; Yuanqing Zhang; Minhao Wu; The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharmaceutica Sinica B 2018, 8, 539-551, 10.1016/j.apsb.2018.03.001.
  16. Michael Ryan Weist; Renate Starr; Brenda Aguilar; Junie Chea; Joshua K. Miles; Erasmus Poku; Ethan Gerdts; Xin Yang; Saul J. Priceman; Stephen J Forman; et al.David ColcherC. E. BrownJohn E. Shively PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine. Journal of Nuclear Medicine 2018, 59, 1531-1537, 10.2967/jnumed.117.206714.
  17. Nahid Yusufi; Sabine Mall; Henrique De Oliveira Bianchi; Katja Steiger; Sybille Reder; Richard Klar; Stefan Audehm; Mona Mustafa; Stephan Nekolla; Christian Peschel; et al.Markus SchwaigerAngela M KrackhardtCalogero D'alessandria In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET. Theranostics 2017, 7, 2402-2416, 10.7150/thno.17994.
  18. Aditya Bansal; Mukesh K. Pandey; Yunus E Demirhan; Jonathan J Nesbitt; Ruben J Crespo-Diaz; Andre Terzic; Atta Behfar; Timothy R. DeGrado; Novel (89)Zr cell labeling approach for PET-based cell trafficking studies.. EJNMMI Research 2015, 5, 19, 10.1186/s13550-015-0098-y.
  19. Binxia Yang; Akshaar Brahmbhatt; Evelyn Nieves Torres; Brian Thielen; Deborah L. McCall; Sean Engel; Aditya Bansal; Mukesh K. Pandey; Allan B. Dietz; Edward B. Leof; et al.Timothy R. DeGradoDebabrata MukhopadhyaySanjay Misra Tracking and Therapeutic Value of Human Adipose Tissue–derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology 2016, 279, 513-522, 10.1148/radiol.2015150947.
  20. Clara T. Nicolas; Raymond D. Hickey; Kari L. Allen; Zeji Du; Rebekah M. Guthman; Robert A. Kaiser; Bruce Amiot; Aditya Bansal; Mukesh K. Pandey; Lukkana Suksanpaisan; et al.Timothy R DeGradoScott L. NybergJoseph Benjamin Lillegard Hepatocyte spheroids as an alternative to single cells for transplantation after ex vivo gene therapy in mice and pig models.. Surgery 2018, 164, 473-481, 10.1016/j.surg.2018.04.012.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Joon-Kee Yoon
,
Bok-Nam Park
,
Eun-Kyoung Ryu
,
Young-Sil An
,
Su-Jin Lee
View Times: 607
Revision: 1 time (View History)
Update Date: 22 Jun 2020
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback